drugset / Trial / NCT03181763

Evaluation of MDMA on Startle Response

NCT03181763

Phase 1 Completed 34 enrolled Resilient Pharmaceuticals
RandomizedParallel-groupDouble-blindBasic science

Summary

The goal of this clinical trial is to learn if MDMA impacts startle response in healthy participants. The main question it aims to answer is: Does MDMA impact participant's performance on a startle test? Researchers will compare healthy volunteers who have taken MDMA to those who have taken placebo. Participants will first undergo a 1-hour startle test. The next day, they will be randomized to receive either MDMA or placebo followed by another startle test and vitals signs and blood measurements. Participants will return the next day for a final startle test. Their sleep will be tracked by a Fitbit device.

Timeline

Start
2017-03-14
Primary completion
2020-08-01
Completion
2020-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Midomafetamine Unknown 100 mg

Indications

No indication recorded.